Nurix Therapeutics, Inc. (NRIX) Stock Analysis
Breakout setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $17.14: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 4.62; Below-average business quality.
Nurix Therapeutics is a clinical-stage biopharma developing targeted protein degraders using its DEL-AI discovery platform. Its three wholly owned clinical candidates are bexobrutideg (BTK degrader, Phase 2 potentially pivotal for CLL), zelebrudomide (dual BTK/Ikaros/Aiolos... Read more
Sell if holding. Engine safety override at $17.14: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 4.62; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 48, MACD bullish. Score 4.5/10, moderate confidence.
Passes 9/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.60, news boost analyst cluster(3), earnings proximity 24d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
About Nurix Therapeutics, Inc.
About Nurix Therapeutics, Inc.
Nurix Therapeutics advances three wholly-owned clinical-stage drug candidates through its DEL-AI targeted protein degradation platform, with bexobrutideg entering a Phase 2 potentially pivotal CLL trial in October 2025 following FDA agreement on the 600 mg once-daily dose. The company had received $482 million in non-dilutive collaboration funding through November 30, 2025, and is eligible for up to $6.1 billion in potential milestones and royalties from partnerships with Gilead Sciences, Sanofi, and Pfizer.
Nurix generates revenue through collaboration agreements granting partners access to its DEL-AI discovery engine, retaining co-development, co-commercialization, and profit-sharing options in the United States for multiple drug candidates. Bexobrutideg (NX-5948) targets BTK in patients who have failed three prior lines of therapy — a covalent BTK inhibitor, a BCL2 inhibitor, and a non-covalent BTK inhibitor — the same triple-refractory population for which no approved standard of care exists. A second BTK program, zelebrudomide (NX-2127), is in Phase 1 dose escalation in aggressive B-cell lymphomas including DLBCL and MCL following a partial clinical hold resolved in August 2024. A third asset, NX-1607, an oral CBL-B inhibitor, is in Phase 1 across multiple solid tumor indications. Partnered programs include GS-6791/NX-0479, an IRAK4 degrader for which FDA cleared an IND in April 2025, and NX-3911, a STAT6 degrader that Sanofi licensed in June 2025. Manufacturing and clinical supplies are sourced through third-party contract manufacturers.
Show full overview
Bexobrutideg's Phase 2 DAYBreak trial, designed as a potentially pivotal study seeking Accelerated Approval in relapsed or refractory CLL patients, represents the company's most critical near-term binary event. The 10-K notes that no regulatory authority has approved any targeted protein degrader therapeutic, making this an unproven modality subject to additional regulatory scrutiny beyond established drug classes. Bexobrutideg received FDA Fast Track designation in CLL/SLL in January 2024 and EMA PRIME designation in November 2024 — regulatory milestones that may accelerate review timelines but do not reduce clinical evidence requirements.
See also: Healthcare · Biotechnology
From Nurix Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Nurix Therapeutics, Inc.
Latest news
- NEWS Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target — benzinga Jun 15, 2026 positive
- NEWS Nurix to Present Updated CLL Drug Data at EHA 2026, Says Bexobrutideg Shows Durable Responses in CLL Trial — benzinga Jun 11, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Nurix Therapeutics, Maintains $32 Price Target — benzinga Jun 10, 2026 positive
- NEWS Truist Securities Maintains Buy on Nurix Therapeutics, Raises Price Target to $32 — benzinga Jun 9, 2026 positive
- NEWS Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday — benzinga Jun 9, 2026 neutral
Generated 2026-06-17T09:12:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.14: Quality below floor (1.8 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10 and A.R:R 4.2:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Elevated put/call ratio: 4.62; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 48, MACD bullish. Prior stop was $15.93. Score 4.5/10, moderate confidence.
Take-profit target: $27.90 (+62.9% upside). Prior stop was $15.93. Stop-loss: $15.93.
Quality below floor (1.8 < 4.0).
Nurix Therapeutics, Inc. trades at a P/E of N/A (forward -6.3). TrendMatrix value score: 5.4/10. Verdict: Sell.
23 analysts cover NRIX with a consensus score of 4.3/5. Average price target: $31.
What does Nurix Therapeutics, Inc. do?Nurix Therapeutics is a clinical-stage biopharma developing targeted protein degraders using its DEL-AI discovery...
Nurix Therapeutics is a clinical-stage biopharma developing targeted protein degraders using its DEL-AI discovery platform. Its three wholly owned clinical candidates are bexobrutideg (BTK degrader, Phase 2 potentially pivotal for CLL), zelebrudomide (dual BTK/Ikaros/Aiolos degrader, Phase 1/2), and NX-1607 (CBL-B inhibitor, Phase 1). Revenue comes entirely from collaborations with Gilead, Sanofi, and Pfizer; $482M received through November 2025.